RYAH Medtech Inc revealed Thursday that the company’s dose-measuring dry herb inhaler has passed key medical device compliance tests.
In a statement, the privately-owned New York-based company said it cleared the CE-RED NB and IEC 60601 medical device safety tests, which constitute technical standards for the safety and performance of medical electrical equipment, published by the International Electrotechnical Commission.
RYAH Medtech said it is a widely accepted benchmark and compliance with IEC60601 has become a requirement for the commercialization of electrical medical equipment in many countries.
READ: RYAH Medtech data finds 78% of male medical cannabis patients use cannabis daily or near-daily, start treatment earlier in life
“RYAH’s distinct objective is to provide the most comfortable and secure experience for patients utilizing plant-based treatment options. The completion of the IEC 60601 device safety test directive marks a new milestone for RYAH and reconfirms our intention to architect the highest quality delivery solutions for plant-based medicine,” said RYAH Medtech CEO Gregory Wagner.
“As we continue to focus on transforming patient care with accurate data analytics and perfecting our safety model, countries around the world are quickly and permanently reshaping their understanding of plant-based medicine: they tend to only embrace the devices which meet and exceed stringent safety standards,” he added.
The RYAH Medtech boss noted that completing the safety test enabled the company to initiate global medical registration applications while RYAH continued to move forward towards its Canadian Securities Exchange listing.
Designed to give patients control, the RYAH inhaler measures inhalations to deliver precise and predictable results. It connects to a mobile app with features like stat-tracking and pre-sets for temperature and dosage that are customized to individual needs.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive
